Exceeding 300 cases in Sacra Hospital that first launched the robot
Planning 3 additional units to be supplied to orthopedic surgeons in India this month
CUVIS Joint, an artificial joint surgery robot independently developed by Curexo, is also revitalizing overseas medical fields.
Curexo had successfully completed a congratulatory ceremony for the 100th artificial joint robotic surgery case at SaiShree Hospital. This convention hosted by Merrill Healthcare, the largest implant company in India that purchased the Cuvis-Joint, was held at the JW Marriott Hotel in Pune, India, and about 300 officials attended.
Since the daily average number of confirmed COVID-19 cases decreased to 30,000 to 40,000 in the second half of the year, SaiShree Hospital performed full-scale robotic joint surgery and successfully achieved 100 cases.
In addition to SaiShreei Hospital, Sakra World Hospital, the first hospital in India to introduce Cuvis-joints, also recently completed 300 cases- following 100 cases in February this year and 200 cases in August this year- by actively implementing robotic surgery for artificial joints.
Moreover, by using Cuvis-Joint on robotic artificial joint surgery, Sakra World Hospital and SaiShree Hospital are training orthopedic surgeons located across India. They have produced more than 70 doctors who have completed this training course so far.
A specialist from SaiShree Hospital who attended the ceremony mentioned the advantages of Cuvis-Joint. He said, "compared to other robots, Cuvis-Joint is a fully automatic active surgical robot that provides optimal surgical results and shortens the preparation time for surgery with simple calibration."
A staff from Curexo said, "Three units of Cuvis-Joint ordered in the third quarter of October will be installed at an orthopedic surgeon in India through Merrill Healthcare, and additional supply contracts are being discussed."
He added, "As Cuvis-Joint is an open platform that can use a variety of implants, it will further expand its supply opportunities to artificial joint hospitals through contracts with major implant companies in the future."
